IL169362A0 - Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders - Google Patents
Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disordersInfo
- Publication number
- IL169362A0 IL169362A0 IL169362A IL16936205A IL169362A0 IL 169362 A0 IL169362 A0 IL 169362A0 IL 169362 A IL169362 A IL 169362A IL 16936205 A IL16936205 A IL 16936205A IL 169362 A0 IL169362 A0 IL 169362A0
- Authority
- IL
- Israel
- Prior art keywords
- tolterodine
- treating urinary
- urinary disorders
- reduced dose
- antimuscarinic agents
- Prior art date
Links
- 239000003149 muscarinic antagonist Substances 0.000 title abstract 2
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 title abstract 2
- 229960004045 tolterodine Drugs 0.000 title abstract 2
- 230000002485 urinary effect Effects 0.000 title abstract 2
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 title abstract 2
- 206010020853 Hypertonic bladder Diseases 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010013781 dry mouth Diseases 0.000 abstract 1
- 208000020629 overactive bladder Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44169003P | 2003-01-22 | 2003-01-22 | |
| PCT/IB2004/000169 WO2004064821A1 (en) | 2003-01-22 | 2004-01-14 | Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL169362A0 true IL169362A0 (en) | 2007-07-04 |
Family
ID=32771960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL169362A IL169362A0 (en) | 2003-01-22 | 2005-06-23 | Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20060047007A1 (https=) |
| EP (1) | EP1589958B2 (https=) |
| JP (1) | JP2006515607A (https=) |
| KR (1) | KR20050096147A (https=) |
| CN (1) | CN1741796A (https=) |
| AT (1) | ATE432070T1 (https=) |
| AU (1) | AU2004206110A1 (https=) |
| BR (1) | BRPI0406861A (https=) |
| CA (1) | CA2514022C (https=) |
| DE (1) | DE602004021233D1 (https=) |
| ES (1) | ES2324712T5 (https=) |
| IL (1) | IL169362A0 (https=) |
| MX (1) | MXPA05007767A (https=) |
| PL (1) | PL377995A1 (https=) |
| TW (1) | TW200418447A (https=) |
| WO (1) | WO2004064821A1 (https=) |
| ZA (1) | ZA200505026B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8709476B2 (en) | 2003-11-04 | 2014-04-29 | Supernus Pharmaceuticals, Inc. | Compositions of quaternary ammonium compounds containing bioavailability enhancers |
| DK2210605T3 (en) * | 2003-11-04 | 2017-05-22 | Tcd Royalty Sub Llc | Daily single dose doses of trospium. |
| ES2322148T3 (es) * | 2004-08-11 | 2009-06-17 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Medicamentos que contienen anticolinergicos para el tratamiento en las vias urinarias. |
| PT1986642E (pt) * | 2006-02-13 | 2014-01-30 | Orient Pharma Samoa Co Ltd | Combinação de agonista do receptor alfa-2 (clonidina) e um agente antimuscarínico (oxibutinina) para o tratamento de sialorreia |
| WO2009019599A2 (en) | 2007-08-08 | 2009-02-12 | Themis Laboratories Private Limited | Extended release compositions comprising tolterodine |
| WO2011109403A1 (en) * | 2010-03-01 | 2011-09-09 | Xenoport, Inc. | Use of (3r)-4-{[(1s)-2-methyl-1- (2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5382600A (en) | 1988-01-22 | 1995-01-17 | Pharmacia Aktiebolag | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
| SE8800207D0 (sv) | 1988-01-22 | 1988-01-22 | Kabivitrum Ab | Nya aminer, deras anvendning och framstellning |
| JP2000515525A (ja) | 1996-07-19 | 2000-11-21 | アベーグ，グンナー | 尿と胃腸の疾患の治療におけるｓ（―）―トルテロジン |
| SK287111B6 (sk) * | 1998-08-27 | 2009-12-07 | Pharmacia & Upjohn Ab | Farmaceutický prípravok obsahujúci tolterodin s regulovaným uvoľňovaním |
| SE9803871D0 (sv) * | 1998-11-11 | 1998-11-11 | Pharmacia & Upjohn Ab | Therapeutic method and formulation |
| NZ518309A (en) * | 1999-11-11 | 2003-05-30 | Pharmacia Ab | Controlled release tolterodine formulation that releases not less than 80% of the active compound in under 18 hours |
-
2004
- 2004-01-14 MX MXPA05007767A patent/MXPA05007767A/es unknown
- 2004-01-14 DE DE602004021233T patent/DE602004021233D1/de not_active Expired - Lifetime
- 2004-01-14 CN CNA2004800025658A patent/CN1741796A/zh active Pending
- 2004-01-14 WO PCT/IB2004/000169 patent/WO2004064821A1/en not_active Ceased
- 2004-01-14 BR BR0406861-0A patent/BRPI0406861A/pt not_active IP Right Cessation
- 2004-01-14 KR KR1020057013495A patent/KR20050096147A/ko not_active Ceased
- 2004-01-14 AT AT04702017T patent/ATE432070T1/de not_active IP Right Cessation
- 2004-01-14 ES ES04702017T patent/ES2324712T5/es not_active Expired - Lifetime
- 2004-01-14 PL PL377995A patent/PL377995A1/pl not_active Application Discontinuation
- 2004-01-14 AU AU2004206110A patent/AU2004206110A1/en not_active Abandoned
- 2004-01-14 JP JP2006500313A patent/JP2006515607A/ja active Pending
- 2004-01-14 EP EP04702017A patent/EP1589958B2/en not_active Expired - Lifetime
- 2004-01-14 CA CA2514022A patent/CA2514022C/en not_active Expired - Fee Related
- 2004-01-20 TW TW093101626A patent/TW200418447A/zh unknown
- 2004-01-22 US US10/762,726 patent/US20060047007A1/en not_active Abandoned
-
2005
- 2005-06-21 ZA ZA200505026A patent/ZA200505026B/xx unknown
- 2005-06-23 IL IL169362A patent/IL169362A0/en unknown
-
2007
- 2007-02-21 US US11/677,071 patent/US20070155838A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2324712T5 (es) | 2012-06-08 |
| TW200418447A (en) | 2004-10-01 |
| BRPI0406861A (pt) | 2006-01-03 |
| DE602004021233D1 (de) | 2009-07-09 |
| ES2324712T3 (es) | 2009-08-13 |
| JP2006515607A (ja) | 2006-06-01 |
| CN1741796A (zh) | 2006-03-01 |
| KR20050096147A (ko) | 2005-10-05 |
| EP1589958B1 (en) | 2009-05-27 |
| WO2004064821A1 (en) | 2004-08-05 |
| ZA200505026B (en) | 2006-07-26 |
| CA2514022C (en) | 2010-07-13 |
| ATE432070T1 (de) | 2009-06-15 |
| CA2514022A1 (en) | 2004-08-05 |
| PL377995A1 (pl) | 2006-02-20 |
| US20060047007A1 (en) | 2006-03-02 |
| US20070155838A1 (en) | 2007-07-05 |
| MXPA05007767A (es) | 2006-01-31 |
| AU2004206110A1 (en) | 2004-08-05 |
| EP1589958A1 (en) | 2005-11-02 |
| EP1589958B2 (en) | 2012-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04003866A (es) | Agente-antimuscarnico y agonista de estrogeno para tratar la vejiga inestable o hiperactiva. | |
| WO2002042462A3 (en) | Therapeutic agents and methods of use thereof for treating an amyloidogenic disease | |
| EP1600167A3 (en) | A pyrrolidineacetamide derivative alone in combination for treatment of CNS disorders | |
| WO2002038142A3 (en) | Serotonergic compositions and methods for treatment of mild cognitive impairment | |
| PY0108909A (es) | Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero | |
| PL366430A1 (en) | Sustained release formulations of oxymorphone | |
| AU3846901A (en) | Oral, nasal and pulmonary dosage formualtions of copolymer 1 | |
| WO2002066427A3 (en) | (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof | |
| GB0406384D0 (en) | Composition for reducing appetite in mammals comprising proxyanidin | |
| ZA200505026B (en) | Reduced dose of tolterodine and other antimuscarinic agents for treating urinary disorders | |
| EP1262197A3 (en) | Combination treatment for sleep disorders including sleep apnea | |
| UA42719C2 (uk) | Сполуки, композиції та способи, які інгібують протеази, для лікування та профілактики імуномедіаторних запальних хвороб | |
| WO2003049667A3 (en) | The method of treating cancer | |
| WO2003015690A3 (en) | Method for treating primary insomnia | |
| CA2432177A1 (en) | Drug for prevention and/or therapy of endometriosis | |
| JPS56142213A (en) | Pharmacuetical blend for treating parkinsonism syndrome | |
| MXPA04001805A (es) | Nueva forma de dosificacion oral de liberacion prolongada. | |
| WO2002091990A3 (en) | Prevention of addiction in pain management | |
| IL162391A0 (en) | Method of treatment | |
| EP1260221A3 (en) | Combination treatment for depression and anxiety | |
| WO2001028541A3 (en) | Composition comprising sildenafil and l-arginine | |
| WO2001039760A3 (en) | Method of treating batten disease | |
| EP1584333A3 (en) | Use of acetylcoenzime A inhibitors for treating Alzheimer's disease | |
| MXPA02007454A (es) | Compuestos utiles para tratamiento o prevencion de una enfermedad mediada por el alfa-2b-adrenoceptor. | |
| RU2006146071A (ru) | Средство для устранения фактора циркуляторной дисфункции |